KLRB1 and neoplasm: Researchers found that CD161 can suppress T cell anti-tumor immunity in glioma, and knocking down KLRB1 or using an antibody-mediated blockade of CD161 can enhance the ability of T cells to kill tumors (Mathewson et al., 2021).